Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.